"Abbott's 2023 Q4 Earnings: Medical Devices Drive Double-Digit Growth, 2024 Outlook Below Estimates"
TL;DR Summary
Abbott reported its fourth-quarter and full-year 2023 financial results, with a 1.5% increase in fourth-quarter sales and an 8.1% decrease in full-year sales due to a decline in COVID-19 testing-related sales. The company issued its 2024 financial outlook, projecting full-year organic sales growth of 8.0% to 10.0%. Abbott's R&D pipeline continues to deliver new products, and the company anticipates growth in 2024 and beyond. The company's diverse portfolio, including infant formula, laboratory automation systems, and diabetes care products, contributed to its success in 2023.
- Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook Press Releases
- Abbott forecasts 2024 earnings largely below estimates, shares down Yahoo Finance
- Abbott Laboratories Stock Is Down. Earnings, Sales Aren’t the Problem. Barron's
- Infographic: Highlights of Abbott Laboratories’ (ABT) Q4 2023 earnings report AlphaStreet
- Abbott reports double-digit growth across Medical Devices in Q4 as Diabetes, EP lead the way Mass Device
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
28 min
vs 28 min read
Condensed
98%
5,598 → 84 words
Want the full story? Read the original article
Read on Press Releases